°æÈñ´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú ¹Ú¼Ò¿µ ¼ö¼®Àü°øÀÇÀÇ ³í¹®ÀÌ ÃÖ±Ù ÀϺ»³»ºÐºñÇÐȸ¿¡¼ Ãâ°£ÇÏ´Â ±¹Á¦ÇмúÀâÁö Endocrine Journal¿¡ °ÔÀçµÇ¾ú´Ù.
¹Ú¼Ò¿µ Àü°øÀÇÀÇ ³í¹®Àº sarpogrelate¶ó´Â ¾à¹°ÀÌ 2Çü ´ç´¢È¯ÀÚÀÇ ´ëÇ÷°ü ÇÕº´Áõ Ä¡·áÁ¦·Î ±âÁ¸¿¡ »ç¿ëµÇ´ø ¾Æ½ºÇǸ°°ú ºñ±³ÇØ À¯»çÇÑ È¿°ú°¡ ÀÖ´Ù´Â ³»¿ëÀ» ´ã°í ÀÖ´Ù.
Çѱ¹ÀÎ 2Çü ´ç´¢È¯ÀÚ Áß ÀϺΰ¡ ¾Æ½ºÇǸ° ºÎÀÛ¿ë°ú ÇÕº´ÁõÀ¸·Î ½ÉÇ÷°üÁúȯ ¿¹¹æ ¾à¹° Åõ¿©°¡ ¾î·Á¿ü´ø ¸¸Å sarpogrelate°¡ ±× ´ë¾ÈÀ¸·Î »ç¿ëµÉ ¼ö ÀÖÀ½À» ½Ã»çÇß´Ù´Â µ¥ Å« ÀÇÀÇ°¡ ÀÖ´Ù.
Á¦¸ñÀº ‘2Çü ´ç´¢º´ ȯÀÚÀÇ ´ëÇ÷°ü ÇÕº´Áõ À§ÇèÀÎÀÚ¿¡ ´ëÇÑ sarpogrelate È¿°ú Æò°¡(Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes)’ÀÌ¸ç ¿¬±¸´Â °æÈñ´ëº´¿øÀ» ºñ·ÔÇÑ ±¹³» 3°³ ´ëÇк´¿ø¿¡¼ ÇÔ²² ½ÃÇàµÈ ¹«ÀÛÀ§ ´ëÁ¶ Àӻ󿬱¸ °á°ú¿¡ ±Ù°ÅÇß´Ù.